Intravesical OnabotulinumtoxinA Injection for Overactive Orthotopic Ileal Neobladder: Feasibility and Efficacy
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
The efficacy of intravesical onabotulinumtoxinA (BTXA) in the treatment of overactive bladder (OAB) has been well documented. The use of BTXA injection in orthotopic neobladders is yet to be studied. We present 4 cases of patients injected with intravesical BTXA for overactive orthotopic ileal neobladder. We recorded patient demographics, presenting and follow-up symptoms, urodynamic profiles, and Patient Global Impression of Improvement (PGI-I) scores. The 4 patients reported varying degrees of subjective improvements in the symptoms, including urgency, urge incontinence, and pad usage. Mean followup duration was 8.3 months (range, 5–14 months). Average PGI-I score was 3 (“a little better”) (range, 2–4). To our knowledge, the current study is the first case series examining BTXA injection for orthotopic neobladder overactivity. BTXA injection yielded varying degrees of objective and subjective improvements, without significant complications. Intravesical BTXA injection is feasible and may be considered as a potential treatment alternative for OAB in orthotopic neobladders, although further study is warranted.
Abstract
The efficacy of intravesical onabotulinumtoxinA (BTXA) in the treatment of overactive bladder (OAB) has been well documented. The use of BTXA injection in orthotopic neobladders is yet to be studied. We present 4 cases of patients injected with intravesical BTXA for overactive orthotopic ileal neobladder. We recorded patient demographics, presenting and follow-up symptoms, urodynamic profiles, and Patient Global Impression of Improvement (PGI-I) scores. The 4 patients reported varying degrees of subjective improvements in the symptoms, including urgency, urge incontinence, and pad usage. Mean followup duration was 8.3 months (range, 5–14 months). Average PGI-I score was 3 (“a little better”) (range, 2–4). To our knowledge, the current study is the first case series examining BTXA injection for orthotopic neobladder overactivity. BTXA injection yielded varying degrees of objective and subjective improvements, without significant complications. Intravesical BTXA injection is feasible and may be considered as a potential treatment alternative for OAB in orthotopic neobladders, although further study is warranted.
참고문헌 (10)
- Madersbacher S, "Long-term voiding pattern of patients with ileal orthotopic bladder substitutes", J Urol, 167, pp.2052~2057 (2002)
- Yalcin I, "Validation of two global impression questionnaires for incontinence", Am J Obstet Gynecol, 189, pp.98~101 (2003)
- el-Bahnasawy MS, "Persistent and occasional nocturnal enuresis in orthotopic urinary diversion:is there a urodynamic difference?", BJU Int, 96, pp.1373~1377 (2005)
- Ciceron C, "Botulinum toxin type A injections in the augmented bladder after failure of augmentation enterocystoplasty in neurological patients:a retrospective multicenter study", Ann Phys Rehabil Med, 56, pp.e232~e233 (2013)
- Apostolidis A, "Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity", Eur Urol, 49, pp.644~650 (2006)
- Smith CP, "Emerging role of botulinum toxin in the management of voiding dysfunction", J Urol, 171(6 Pt 1), pp.2128~2137 (2004)
- Dmochowski R, "Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial", J Urol, 184, pp.2416~2422 (2010)
- Cruz F, "Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial", Eur Urol, 60, pp.742~750 (2011)
- Ginsberg D, "Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity", J Urol, 187, pp.2131~2139 (2012)
- Nitti VW, "Botulinum toxin for the treatment of idiopathic and neurogenic overactive bladder: state of the art", Rev Urol, 8, pp.198~208 (2006)